Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2017 financial
Toggle Summary Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc . (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker , Chief Executive Officer, will present at the